ERS Genomics signs CRISPR patent deal on industrial applications
16-10-2018
ERS extends CRISPR influence with two licensing deals
20-09-2018
ralwel / iStockphoto.com
The company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, ERS Genomics, has signed a patent licensing deal with DefiniGEN, a spin-out from the University of Cambridge, UK.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
ERS Genomics, patent licence, CRISPR, patent, Cambridge University, DefiniGEN
